nubeqa
bayer ag - darolutamide - prostatahyperplasie neubildungen, kastration-resistentem - endokrine therapie - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.
nubeqa 300 mg filmtabletten
bayer (schweiz) ag - darolutamidum - filmtabletten - darolutamidum 300 mg, calcii hydrogenophosphas, carmellosum natricum conexum corresp. natrium 2.7 mg, lactosum monohydricum, magnesii stearas, povidonum k 30, Überzug: hypromellosum, lactosum monohydricum, macrogolum 3350, e 171, pro compresso obducto corresp. lactosum monohydricum 186 mg. - nicht-metastasiertes, kastrationsresistentes prostatakarzinom (nmcrpc); metastasiertes, hormon-sensitives prostatakarzinom (mhspc) - synthetika
candesartan/hct +pharma 8 mg/12,5 mg tabletten
+pharma arzneimittel gmbh - candesartan cilexetil; hydrochlorothiazid -
candesartan/hct +pharma 16 mg/12,5 mg tabletten
+pharma arzneimittel gmbh - candesartan cilexetil; hydrochlorothiazid -
enalapril/hct +pharma tabletten
+pharma arzneimittel gmbh - enalapril maleat; hydrochlorothiazid - enalapril und diuretika
valsartan/hct +pharma 160 mg/12,5 mg filmtabletten
+pharma arzneimittel gmbh - hydrochlorothiazid; valsartan -
valsartan/hct +pharma 80 mg/12,5 mg filmtabletten
+pharma arzneimittel gmbh - hydrochlorothiazid; valsartan -
candesartan/amlodipin/hct +pharma 16 mg/10 mg/12,5 mg hartkapseln
+pharma arzneimittel gmbh - amlodipin besilat; candesartan cilexetil; hydrochlorothiazid -
candesartan/amlodipin/hct +pharma 16 mg/5 mg/12,5 mg hartkapseln
+pharma arzneimittel gmbh - amlodipin besilat; candesartan cilexetil; hydrochlorothiazid -
valsartan/hct +pharma 160 mg/25 mg filmtabletten
+pharma arzneimittel gmbh - hydrochlorothiazid; valsartan -